GEN-MKT-18-7897-A
Sep 17, 2021 | Blogs, Environmental / Industrial | 0 comments
Read time: 2 minutes
According to a recent study from Harvard University, the US EPA, and NIEHS, traditional targeted analysis techniques poorly characterize the PFAS composition of contemporary PFAS-based firefighting foams, know as aqueous film-forming foams (AFFF). Using the EPA 533 PFAS drinking water method for the analyte list, the researchers found that targeted mass spectrometry methods accounted for <1% of organic fluorine content. This is important because it demonstrates that targeted analysis methods miss nearly all the PFAS compounds in modern AFFF mixtures, thus underestimating the risk to human health and the environment.
In the second episode of PFAS Fireside chats, the lead author, Bridger Ruyle, joined me to discuss the study’s main findings and implications. Bridger is a PhD student in Environmental Science and Engineering at the Harvard John A. Paulson School of Engineering and Applied Science.
The study examined both legacy and modern commercial AFFF mixtures. AFFF are used to combat petroleum-based fires by creating a barrier between the fire and air, and they are they used extensively at airports and by the military around the globe.
If targeted analytical methods don’t adequately capture all the PFAS compounds in a sample, how did the researchers know what they were missing? First, the researchers used techniques such as “extractable organofluorine (EOF)” to quantify the total potential PFAS compounds in the AFFF mixtures. That is how they showed their targeted methods were missing a substantial portion of the PFAS. Next, they used high-resolution accurate mass spectrometry to identify the unknown PFAS.
So, what’s in these modern AFFF mixtures? It turns out that >90% of the PFAS compounds are 6:2 fluorotelomer-based compounds. While the exact fate of these isn’t well understood, they could potentially degrade to very persistent PFAS compounds, several of which are covered by various state and federal regulations.
The study focused on commercial AFFF mixtures, but what does it look like in the real-world environment where AFFF releases have impacted the surface and groundwater? Bridger and his colleagues addressed that question in a follow-up paper, and perhaps we will talk about it in a future episode of PFAS Fireside chats.
*This content does not constitute legal advice. You should consult counsel to assure your procedures comply with applicable law and that it meets your needs.
RUO-MKT-18-13829-A
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network